LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K Filing
Lixte Biotechnology entered into a Securities Purchase Agreement with accredited investors to issue and sell 2,366,503 shares of common stock and Pre-Funded Warrants for an additional 258,859 shares at $6.31 per share (or $6.30 per warrant), raising approximately $16.6 million in gross proceeds on June 4, 2026. (Items: 1.01 Entry Into a Material Definitive Agreement On June 2, 2026, Lixte Biotechnology Holdings, Inc, 8.01 Other Events, 9.01 Financial Statements and Exhibits (d) Exhibits)
Tickers: $LIXT